Levodopa en la enfermedad de Parkinson: ¿Qué hemos aprendido? / Levodopa for Parkinson's disease: What have we learned?
Rev. méd. Chile
; 134(7): 893-901, jul. 2006. ilus, tab
Artigo
em Espanhol
| LILACS
| ID: lil-434592
Biblioteca responsável:
BR1.1
ABSTRACT
Parkinson's disease (PD) is the second most common neurodegenerative disease in the world. Dopamine deficit is the cornerstone of its clinical manifestations. Levodopa, the main treatment for this condition, was first used for PD more than 40 years ago and today it still is the most powerful treatment for this disease. In recent years many advances have been made for understanding of the neurochemical mechanisms of this drug. Furthermore, new insights about the genesis of motor complications secondary to its use are known, specially related with the mode of its administration. This article updates the pharmacology of levodopa and its implications for the pathophysiology and treatment of PD. The new available presentations of levodopa are also reviewed. The implications of these advances for the treatment of this disease are commented.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
LILACS
Assunto principal:
Doença de Parkinson
/
Dopaminérgicos
/
Levodopa
/
Antiparkinsonianos
Tipo de estudo:
Estudo de etiologia
Limite:
Humanos
País/Região como assunto:
América do Sul
/
Chile
Idioma:
Espanhol
Revista:
Rev. méd. Chile
Assunto da revista:
Medicina
Ano de publicação:
2006
Tipo de documento:
Artigo
País de afiliação:
Chile
Instituição/País de afiliação:
Pontificia Universidad Católica de Chile/CL
/
Universidad de Santiago de Chile/CL